Neurothera Labs

Neurothera Labs FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Neurothera Labs (NTLX.V) as of Nov 2, 2026 is 40.26 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 55.11 % — a change of -26.94% (lower).

FCF Conversion

40.26 %

YoY

-26.94%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Neurothera Labs is 2026 40.26 % . FCF Conversion Rate (FCF/EBITDA) of Neurothera Labs was 2025 55.11 % . It decreases by -26.94% lower compared to the previous year.

The Neurothera Labs FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
71.85 CAD
Jan 1, 2023
101.25 CAD
Jan 1, 2024
67.30 CAD
Jan 1, 2025
55.11 CAD
Jan 1, 2026
40.26 CAD
The Neurothera Labs FCF Conversion history
YEARFCF ConversionYoY
40.26 %-26.94%
55.11 %-18.12%
67.30 %-33.53%
101.25 %+40.90%
71.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neurothera Labs Stock analysis

What does Neurothera Labs do? Miza III Ventures, Inc. operates as a capital pool company with no assets or operations. The company identifies and evaluates potential assets or businesses for a qualifying transaction but has not commenced operations. It generates no revenue and has no business activities. The firm does not engage in any commercial activities or generate income. Miza III Ventures, Inc. is a capital pool company focused on identifying and evaluating assets for a qualifying transaction. The company has no assets, no operations, and no revenue. It is not engaged in any business activities and has not started any operations. The company's business model revolves around the potential completion of a qualifying transaction. However, it has not yet identified any assets or businesses for evaluation. Miza III Ventures, Inc. remains inactive with no operational activities or revenue streams. Neurothera Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurothera Labs stock

FCF Conversion Rate (FCF/EBITDA) of Neurothera Labs is 40.26 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Neurothera Labs changed from 55.11 % to 40.26 %, representing a -26.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Neurothera Labs since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Neurothera Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Neurothera Labs

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Neurothera Labs